August 22, 2014 11:51 AM ET


Company Overview of Xoma (US) LLC

Company Overview

Xoma (US) LLC develops and manufactures protein, peptide and antibody biopharmaceuticals. Its products are used for the treatment of bacterial and fungal infections, infectious complications, immunologic, and inflammatory disorders. The company was incorporated in 1999 and is based in Berkeley, California. Xoma (US) LLC operates as a subsidiary of XOMA Ltd.

2910 Seventh Street

Berkeley, CA 94710

United States

Founded in 1999





Key Executives for Xoma (US) LLC

Chief Executive Officer
Age: 77
Compensation as of Fiscal Year 2014.

Xoma (US) LLC Key Developments

Xoma (US) LLC Enters an Amendment to Loan Agreement

XOMA Corporation entered into an amendment to its loan agreement dated as of December 30, 2011, by and among the company's wholly-owned subsidiary Xoma (US) LLC as borrower, the company, XOMA Technology Ltd. and XOMA Ireland Limited as guarantors, and General Electric Capital Corporation as agent and lender, with such other lenders from time to time a party thereto. The original principal amount under the December 2011 loan agreement with General Electric Capital Corporation was $10,000,000, of which a principal amount of $7,857,143 was outstanding immediately prior to the effective date of the amendment. The amendment provides for an additional term loan in the amount of $4,642,857, and an extension of the interest-only monthly repayment period with respect to the aggregate loan obligation of $12,500,000 outstanding following the effective date of the amendment through March 1, 2013, at a stated interest rate of 10.9% per annum. Thereafter, the borrower is obligated to make monthly principal payments of $347,222, plus accrued interest, at a stated interest rate of 10.9% per annum, over a 27-month period commencing on April 1, 2013 and through June 15, 2015, at which time the remaining outstanding principal amount of $3,125,000, plus accrued interest, shall be due. An accrued final payment fee" in the amount of $191,283 was paid on the effective date of the amendment, and a final payment fee" in the amount of $875,000 is payable on the date upon which the outstanding principal amount is required to be repaid in full. Any mandatory or voluntary prepayment of the $12,500,000 will accelerate the due date of the final payment fee, and trigger a prepayment penalty equal to 3% of the outstanding principal amount being prepaid if prepaid on or before September 27, 2013, 2% if prepaid on or before September 27, 2014, and 1% if prepaid after September 27, 2014, but prior to the maturity date.

Similar Private Companies By Industry

Company Name Region
Biodesy, LLC United States
Kibow Biotech, Inc. United States
RayBiotech, Inc. United States
Oxford Biomedical Research Inc. United States
Rinat Neuroscience Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Xoma (US) LLC, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at